Wegovy on the NHS: weight management and heart-risk access

Weight management under NICE TA875

NICE TA875 recommends semaglutide for eligible adults within a specialist multidisciplinary weight-management service, alongside diet and activity support, for up to two years under that recommendation. Its criteria are tighter than the adult licence. You need at least one weight-related condition and usually a BMI of 35 or more, or 30 to 34.9 if you meet the criteria for referral to specialist services.

Lower BMI thresholds, usually 2.5 lower, apply to people from specified ethnic family backgrounds, because cardiometabolic risk starts at a lower BMI. Your service should apply the guidance as written. Simplified rules on commercial websites often get this wrong.

Cardiovascular risk under NICE TA1152

NICE TA1152, published in May 2026, covers semaglutide to reduce major adverse cardiovascular events in people with established cardiovascular disease and overweight or obesity. It applies to treatment up to 2.4 mg weekly. Treat it as its own recommendation. The obesity service's two-year limit and specialist referral rules do not carry over automatically.

Your first GP appointment

Your GP can record your height, weight, related conditions and past treatment, and refer you where appropriate. Bring a current list of medicines and any private GLP-1 history. Explain your health limits and practical goals as well as the brand you would like. Some people need tests, or treatment for another condition, before a weight-management decision.

A referral may lead to wider support before any prescription. Good care can include dietitian input, psychological support, adapted physical activity and other treatments. Ask the service itself about waiting times and availability.

Rules differ across England, Wales, Scotland and Northern Ireland

NICE guidance applies most directly to England, with arrangements for Wales and Northern Ireland. Scotland has its own assessment and commissioning processes. Local health boards and integrated care systems run delivery. A policy from one area may be correct there and wrong as a national rule.

A new MHRA authorisation does not bring NHS funding with it. This matters most for the 7.2 mg dose and for oral Wegovy. Regulatory approval, a funding recommendation and a local prescribing service each arrive at different times.

Questions to ask before you start

Ask who will prescribe, which dose is covered, how your response will be reviewed and what happens when a funded course ends. TA875 includes considering stopping if you have lost less than 5% of your starting weight after six months. Reviews should also weigh side effects and your circumstances.

Private treatment does not transfer to the NHS automatically. A private diagnosis or purchase does not let you skip local criteria. Keep clear records so any move is safe. One team should hold the active prescription, with a plan to avoid gaps or duplicate supplies.